Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,861 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mental Disorders, Severe Clear all
Withdrawn Phase 4 Interventional

Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

NCT00711204
View directory record Official record
Conditions
Severe Alzheimer's Disease
Interventions
Donepezil Hydrochloride (Aricept)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 20, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

NCT00969709
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
38
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 20, 2026, 9:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dopamine Neurotransmission in Major Depression

NCT01659814
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 20, 2026, 9:51 AM EDT
Recruiting Phase 2 Interventional

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

NCT06820723
View directory record Official record
Conditions
Depression, Anxiety, Major Depressive Disorder
Interventions
CYB003, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Patient Characteristics and Cognitive vs. Behavioral Therapies for Depression

NCT04529694
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psychotherapy
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 20, 2026, 9:51 AM EDT
Recruiting No phase listed Observational

Paradoxical Lucidity in Severe End-Stage Dementia

NCT05234866
View directory record Official record
Conditions
Dementia
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 20, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

NCT01152554
View directory record Official record
Conditions
Major Depressive Disorder, MDD, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
93
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 20, 2026, 9:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Complex Dynamic Systems in Mood Disorders

NCT01583569
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 20, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Storytelling Video Intervention for Depressed Primary Care Patients - Open Trial

NCT02309060
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Storytelling Video Intervention (sTVi)
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Pawtucket, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 20, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder

NCT01957410
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 20, 2026, 9:51 AM EDT
Completed No phase listed Observational

Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes

NCT02474680
View directory record Official record
Conditions
Major Depressive Disorder 1
Interventions
Pharmacogenetic testing
Genetic
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 20, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

NCT06267846
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NBI-1070770, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Lemon Grove, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 20, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms

NCT00578669
View directory record Official record
Conditions
Major Depressive Disorder, Nicotine Dependence, Depression
Interventions
Fluoxetine, Dextrose
Drug
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 20, 2026, 9:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Can the Memory Support Intervention Improve Depression Outcome Following Cognitive Therapy?

NCT02938559
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Cognitive Therapy (CT) for depression, Cognitive Therapy (CT) for depression + Memory Support
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 20, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01179516
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
61
States / cities
Little Rock, Arkansas • Carson, California • Cerritos, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 20, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00849693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, fluoxetine, duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 20, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

NCT02285504
View directory record Official record
Conditions
Postpartum Depression
Interventions
SAGE-547
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 20, 2026, 9:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression

NCT02440815
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Problem Solving Therapy
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 20, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Results available

Brain Aging and Treatment Response in Geriatric Depression

NCT01902004
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Depression
Interventions
Escitalopram, Memantine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 20, 2026, 9:51 AM EDT
Completed No phase listed Observational

A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)

NCT07258485
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
23
States / cities
Phoenix, Arizona • Glendale, California • Temecula, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 20, 2026, 9:51 AM EDT
Recruiting No phase listed Observational

Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder

NCT00025935
View directory record Official record
Conditions
Mood Disorder
Interventions
Lithium
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 85 Years
Enrollment
2,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 20, 2026, 9:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glutamate Probes in Adolescent Depression

NCT02307617
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Disorder, Recurrent, Major Depressive Disorder, Remitted
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 21 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 20, 2026, 9:51 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04532749
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Glendale, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 20, 2026, 9:51 AM EDT
Not yet recruiting Phase 2 Interventional

The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.

NCT07810738
View directory record Official record
Conditions
Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
Interventions
Aripiprazole Augmentation, Bupropion Augmentation
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 9:51 AM EDT